PuSH - Publication Server of Helmholtz Zentrum München

Nho, K.* ; Kueider-Paisley, A.* ; MahmoudianDehkordi, S.* ; Arnold, M. ; Risacher, S.L.* ; Louie, G.* ; Blach, C.* ; Baillie, R.A.* ; Han, X.* ; Kastenmüller, G. ; Jia, W.* ; Xie, G.* ; Ahmad, S.* ; Hankemeier, T.* ; van Duijn, C.M.* ; Trojanowski, J.Q.* ; Shaw, L.M.* ; Weiner, M.W.* ; Doraiswamy, P.M.* ; Saykin, A.J.* ; Kaddurah-Daouk, R.*

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.

Alzheimers Dement. 15, 232-244 (2019)
Publ. Version/Full Text Research data DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Introduction: Bile acids (BAs) are the end products of cholesterol metabolism produced by human and gut microbiome co-metabolism. Recent evidence suggests gut microbiota influence pathological features of Alzheimer's disease (AD) including neuroinflammation and amyloid-beta deposition.Method: Serum levels of 20 primary and secondary BA metabolites from the AD Neuroimaging Initiative (n = 1562) were measured using targeted metabolomic profiling. We assessed the association of BAs with the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF) biomarkers, atrophy (magnetic resonance imaging), and brain glucose metabolism ([F-18]FDG PET).Results: Of 23 BAs and relevant calculated ratios after quality control procedures, three BA signatures were associated with CSFA beta(1-42) ("A") and three with CSF p-tau181 ("T") (corrected P < .05). Furthermore, three, twelve, and fourteen BA signatures were associated with CSF t-tau, glucose metabolism, and atrophy ("N"), respectively (corrected P < .05).Discussion: This is the first study to show serum-based BA metabolites are associated with "A/T/N" AD biomarkers, providing further support for a role of BA pathways in AD pathophysiology. Prospective clinical observations and validation in model systems are needed to assess causality and specific mechanisms underlying this association. (C) 2018 Published by Elsevier Inc. on behalf of the Alzheimer's Association.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
14.423
3.339
65
121
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Metabolomics ; Bile Acid ; Alzheimer's Disease ; Amyloid-beta ; Csf Biomarkers ; Brain Glucose Metabolism ; Pet ; Mri ; Gut-liver-brain Axis; Isolated Rat Hepatocytes; Surface-based Analysis; Gut-brain Axis; Cerebrospinal-fluid; Cholesterol-metabolism; Ursodeoxycholic Acid; Oxidative Stress; Random-field; Vitamin-d; Fdg-pet
Language
Publication Year 2019
Prepublished in Year 2018
HGF-reported in Year 2018
ISSN (print) / ISBN 1552-5260
e-ISSN 1552-5279
Quellenangaben Volume: 15, Issue: 2, Pages: 232-244 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place New York, NY [u.a.]
Reviewing status Peer reviewed
POF-Topic(s) 30505 - New Technologies for Biomedical Discoveries
Research field(s) Enabling and Novel Technologies
PSP Element(s) G-503700-001
Scopus ID 85060999700
PubMed ID 30337152
Erfassungsdatum 2018-10-25